01—Abstract
Summary
Summary of the 10-Q/A filed September 12, 2025. Cited figures are marked; the original filing is the authoritative source.
AST SpaceMobile, Inc. (ASTS) filed its quarterly report on September 12, 2025, providing an update on director and executive officer trading plans.
The primary disclosure in this filing pertains to a Rule 10b5-1 sales plan entered into by Dr. Huiwen Yao, the Executive Vice President and Chief Technology Officer. This plan allows for the sale of up to 160,000 shares of Class A Common Stock and is designed to comply with affirmative defense conditions under Rule 10b5-1(c). The plan is set to remain in effect until September 16, 2026, or until all trades are executed, whichever comes first.
While this filing primarily addresses trading plans, it's important for investors to note that no other directors or officers adopted or terminated similar trading plans during the quarter ended June 30, 2025. The existence of this 10b5-1 plan for a key technology executive suggests a potential for future selling pressure on the stock, depending on market conditions and the execution of the plan over its duration. Investors should monitor the trading activity related to this plan and consider it within the broader context of the company's operational progress and financial performance, which are typically detailed in other sections of the 10-Q filing not provided here.
02—Key points
Key Highlights
- Dr. Huiwen Yao, CTO, entered into a Rule 10b5-1 sales plan on June 12, 2025.
- The plan permits the sale of up to 160,000 shares of Class A Common Stock.
- The sales plan is designed to comply with Rule 10b5-1(c) affirmative defense conditions.
- The plan remains active until September 16, 2026, or upon completion of all planned sales.
- No other directors or officers adopted or terminated Rule 10b5-1 trading plans during the quarter.
- Exhibit 31.1 is listed as part of the filing, typically related to certifications by principal executive and financial officers.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-Q/AQ2 FY2025filed September 12, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $1.16M$900K | +28.4% |
| R&D Expenses | $6.39M$4.46M | +43.3% |
| Operating Expenses | $73.95M$63.89M | +15.7% |
| Interest Expense | $5.70M$4.90M | +16.3% |
| Net Income | -$99.39M-$72.55M | −37.0% |
| Shares Outstanding (Basic) | 241.99M141.19M | +71.4% |
| Shares Outstanding (Diluted) | 241.99M141.19M | +71.4% |
05—Questions
Frequently Asked Questions
What is the significance of Dr. Yao's Rule 10b5-1 sales plan?
A Rule 10b5-1 plan allows insiders to pre-arrange the sale of company stock at a predetermined time or based on specific market conditions, providing an affirmative defense against allegations of insider trading. Dr. Yao's plan indicates a potential future sale of up to 160,000 shares, which investors should be aware of as it could influence stock supply.
Are other executives selling stock?
Based on this specific section of the filing, only Dr. Huiwen Yao has adopted a Rule 10b5-1 sales plan. The filing explicitly states that none of the other directors or officers adopted or terminated such plans during the quarter ended June 30, 2025.
When will Dr. Yao's shares be sold?
The sales plan is in effect until September 16, 2026, or until all the trades specified in the plan have been executed, whichever occurs first. The actual timing and volume of sales will depend on the specific terms of the plan and market conditions.
What is Exhibit 31.1?
Exhibit 31.1 typically contains certifications by the Company's principal executive officer and principal financial officer regarding the accuracy and completeness of the quarterly report, as required by SEC rules.
06—Continue